Genprex to Focus Its Clinical Efforts on Oncoprex™ in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC)

Austin, TX & Cambridge, MA – Feburary 5, 2020-  Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today provides a clinical update and focus for its Oncoprex™ immunogene therapy program for 2020, prioritizing the development of Oncoprex […]

5G Network Infrastructure Market Could Reach $4.2 Billion This Year

Palm Beach, FL – February 5, 2020 – A recent report from industry insider Gartner said the worldwide market will spike in value as businesses gear up in preparation of 5G rollouts. The report said that: “The global 5G market is expected to rise in value to $4.2 billion by the end of 2020 as […]

R&D Leading to Supported Progress For Treating Acute Myeloid Leukemia (AML)

Palm Beach, FL –February 5, 2020 – Acute Myeloid Leukemia (AML) research has seen great progress with more researchers are now studying the causes, diagnosis, and treatment of Acute myeloid leukemia (AML) at many medical centers, university hospitals, and other institutions. Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in […]

Moleculin to Seek Accelerated FDA Approval and Plans for Pivotal Phase 2 AML Trial

Following Successful Completion of US Phase 1 Trial   Houston, TX – February 5, 2020 — Moleculin Biotech, Inc., (NASDAQ: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it intends to discuss with the FDA and EMA (European Medicines Agency) […]